Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 6:2022:7774283.
doi: 10.1155/2022/7774283. eCollection 2022.

Analysis of the Application Value of Ultrasound Three-Dimensional Speckle Tracking Technology Combined with Thyroid Autoantibodies and Hormones in the Diagnosis and Treatment of Graves' Disease

Yi Xu  1 , Songxia Peng  2 , Li Qin  2 , Dianjing Sun  1 , Jianlin Geng  1 , Qingqing Liu  1
Affiliations

Analysis of the Application Value of Ultrasound Three-Dimensional Speckle Tracking Technology Combined with Thyroid Autoantibodies and Hormones in the Diagnosis and Treatment of Graves' Disease

Yi Xu et al. Evid Based Complement Alternat Med. .

Retraction in

Abstract

Objective: The aim of the study is to evaluate the application value of three-dimensional speckle tracking imaging (3D-STI) and combined detection of thyroid autoantibodies and hormones in the diagnosis and treatment of Graves' disease.

Methods: A total of 60 patients with Graves' disease enrolled in our hospital from February 2020 to February 2021 were included in the experimental group, and 60 healthy patients after a physical examination during the same period were selected as the control group. No intervention was performed on the control group, and the experimental group received conventional Graves' disease treatment. The levels of thyroid autoantibodies and hormones in the two groups before and after the treatment were measured, and the 3D-STI was performed to compare the 3D-STI strain parameters of the research objects.

Results: A significantly higher level of thyroid autoantibodies in the experimental group than that in the control group before and after the treatment was found (P < 0.001), with a remarkable decline observed after the treatment (P < 0.001). The positive rate of thyroid autoantibodies in the experimental group before the treatment was significantly higher than that in the control group (P < 0.05). After the treatment, the positive rate of TRAb and TPOAb was higher than that of the control group (P < 0.05), and the positive rate of TPOAb was higher than before the treatment. The two groups showed no significant difference in the positive rate of TGAb (P > 0.05). Significant differences were observed in the thyroid hormone levels between the two groups and also between before and after the treatment (P < 0.001). The experimental group garnered significantly higher 3D-STI strain parameters than the control group before the treatment (P < 0.05); after the treatment, the hyperthyroidism of the patients was relieved with a decreased 3D-STI value, but it was still notably higher than the control group (P < 0.05). Remarkably higher positive rates of combined detection before and after the treatment in the experimental group than those in the control group were obtained (P < 0.05).

Conclusion: The combined detection of 3D-STI and thyroid autoantibodies and hormones ensures a better detection rate of Graves' disease and monitors the treatment effect of patients in real time, which provides a basis for clinical diagnosis and treatment and merits clinical promotion and application.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Comparison of thyroid autoantibody levels of study subjects (x¯ ± s, %). The abscissa from left to right is the control group, the experimental group before treatment, and the experimental group after treatment, respectively. #P < 0.001. (a) TRAb level. The TRAb level of the experimental group before and after treatment was significantly higher than that of the control group (37.21 ± 5.22 vs. 11.98 ± 1.22, 25.15 ± 2.41 vs. 11.98 ± 1.22, P < 0.001); the level of TRAb in the experimental group before treatment was significantly higher than after treatment (37.21 ± 5.22 vs. 25.15 ± 2.41, P < 0.001). (b) TPOAb level (%). The TPOAb level of the experimental group before and after treatment was significantly higher than that of the control group (69.65 ± 5.14 vs. 26.54 ± 3.21, 45.26 ± 3.54 vs. 26.54 ± 3.21, P < 0.001); the level of TPOAb was significantly higher than after treatment (69.65 ± 5.14 vs. 45.26 ± 3.54, P < 0.001). (c) TGAb level (%). The TGAb level of the experimental group before and after treatment was significantly higher than that of the control group (28.98 ± 20.11 vs. 5.10 ± 4.98, 13.68 ± 10.14 vs. 5.10 ± 4.98, P < 0.001); the level of TGAb was significantly higher than after treatment (28.98 ± 20.11 vs. 13.68 ± 10.14, P < 0.001).
Figure 2
Figure 2
Comparison of TRAb positive rate (n (%)). The black area is positive, and the gray area is negative; the left, middle, and right are the experimental group before treatment, the experimental group after treatment, and the control group, respectively. #P < 0.05.
Figure 3
Figure 3
Comparison of TPOAb positive rate (n (%)). The black area is positive, and the gray area is negative; the left, middle, and right are the experimental group before treatment, the experimental group after treatment, and the control group, respectively. #P < 0.05.
Figure 4
Figure 4
Comparison of TGAb positive rate (n (%)). The black area is positive, and the gray area is negative; the left, middle, and right pie charts are the experimental group before treatment, the experimental group after treatment, and the control group, respectively. #P < 0.05. The positive rate of TGAb in the experimental group before treatment was significantly higher than that in the experimental group after treatment and the control group (36 vs. 12, 36 vs. 5, P < 0.05).
Figure 5
Figure 5
Comparison of positive rates of combined detection (n (%)). The abscissa is, from left to right, the experimental group before treatment, the experimental group after treatment, and the control group. The ordinate is positive patients (cases). #P < 0.05. The number of positive cases in the experimental group before treatment was 58 (96.7%); the number of positive cases after treatment was 54 (90.0%); and the number of positive cases in the control group was 1 (1.7%).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Imai T., Ohsima J., Hasegawa Y. Diagnosis of Graves’ disease by cerebral venous thrombosis: a case report. Clinical Neurology . 2018;58 - PubMed
    1. Barcellos L. F., Kamdar B. B., Ramsay P. P., et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. The Lancet Neurology . 2006;5(11):924–931. doi: 10.1016/s1474-4422(06)70552-x. - DOI - PubMed
    1. Domenico Sebastiani G., Minisola G., Galeazzi M. HLA class II alleles and genetic predisposition to the antiphospholipid syndrome. Autoimmunity Reviews . 2003;2(6):387–394. doi: 10.1016/s1568-9972(03)00068-5. - DOI - PubMed
    1. Avillion A. E. Chapter Disorders of the Endocrine System: Anatomy, Physiology, and Current Treatment Initiatives . Silver Spring, ML, USA: American Nurses Credentialing Center; 2016.
    1. Tatulashvili S., Baudry C., Sadoul J. L., Bihan H. New perspectives for the diagnosis and prognosis of Graves’ disease. Annales d’Endocrinologie . 2018;79:S31–S39. - PubMed

Publication types

LinkOut - more resources